NeoGenomics Q3 2026 Earnings: Higher-Value Testing Lifts Margins

NeoGenomics (NASDAQ: NEO) reported Q3 2026 revenue of $209.3 million, up 11% from $187.8 million a year earlier, while GAAP diluted loss per share narrowed to $0.06 from $0.21. For the quarter ended September 30, clinical revenue growth and a shift toward higher-value testing helped lift GAAP gross margin to 46% and adjusted EBITDA to $18.7 million. The company also raised its full-year revenue and adjusted EBITDA guidance.

Core Earnings Data

Gross profit increased faster than revenue, rising 20% as GAAP gross margin expanded by 340 basis points. Meanwhile, operating expenses declined 3%, helping the operating loss narrow to $7.9 million from $27.0 million.

The improvement was also visible on a non-GAAP basis: adjusted EBITDA increased 53%, and adjusted net income rose to $11 million from $4 million.

Adjusted gross margin, adjusted net income, and adjusted EBITDA are non-GAAP measures. They exclude items including amortization, stock-based compensation, and certain transition, litigation, acquisition, and other costs where applicable.

Higher-Value Testing Drove Revenue Faster Than Volume

Clinical services revenue increased 13% to $195 million, accounting for most of NeoGenomics’ quarterly revenue. Clinical test volume rose only 2%, but average revenue per clinical test increased 11% to $530. This indicates that pricing and test mix contributed substantially more to growth than overall testing volume.

Next-generation sequencing was the clearest driver within the clinical portfolio. NGS revenue increased 29%, while NGS test volume rose 17%. Management attributed the broader margin improvement to the continuing shift toward higher-value, higher-margin testing modalities.

NeoGenomics also expanded Medicare coverage for RaDaR ST to include immunotherapy treatment-response monitoring in late-stage solid tumors. New agreements with commercial payers brought the company in-network and broadened access and reimbursement for newer tests, although the company did not quantify the revenue contribution from these developments.

Profitability, Cash Flow, and the Balance Sheet

The combination of higher gross profit and lower total operating expenses drove most of the improvement in GAAP profitability. General and administrative expenses declined to $67.1 million from $69.9 million, and the latest quarter had no impairment charge compared with $7.1 million a year earlier. These reductions more than offset higher research and development and sales and marketing spending.

Cash conversion did not improve at the same pace as reported earnings. For the first nine months of 2026, operating cash flow was $2.9 million, compared with $3.9 million in the prior-year period. Changes in operating assets and liabilities used $45.6 million of cash, versus $16.5 million a year earlier. Accounts receivable increased to $213.4 million from $159.2 million at the end of 2025, highlighting the importance of collections and working-capital management.

Cash and cash equivalents declined by $20.3 million during the first nine months to $139.3 million. Over the same period, NeoGenomics spent $25.0 million on property and equipment and $25.0 million on share repurchases. Net convertible senior notes stood at $374.7 million, up from $341.9 million at the end of 2025.

2026 Guidance

NeoGenomics raised both ends of its full-year revenue range, increased adjusted EBITDA guidance, and reduced its expected GAAP net loss. The updated outlook implies approximately 11% revenue growth and 38% adjusted EBITDA growth from fiscal 2025.

The higher outlook requires continued revenue and margin progress in the fourth quarter while maintaining control over operating costs.

Management View

Management plans to continue investing in commercial teams, community channels, and the product pipeline while using operational initiatives to reduce complexity. CEO Tony Zook said the company sees further opportunities for growth and disciplined long-term margin expansion as the portfolio shifts toward higher-value testing.

NeoGenomics also announced a leadership transition. President and COO Warren Stone is scheduled to become CEO and join the board on January 4, 2027, while Zook will move to the executive chairman role.

Risks Investors Should Watch

• Growth depends heavily on revenue per test and mix: Clinical volume increased only 2%, compared with an 11% increase in average revenue per clinical test. Changes in payer mix, reimbursement, or demand for higher-value tests could therefore affect both revenue growth and margins.
• Cash conversion remains limited: Nine-month operating cash flow was only $2.9 million despite a much smaller net loss. Rising accounts receivable and the larger working-capital cash use make billing and collections important areas to monitor.
• Margin targets require execution: The raised adjusted EBITDA outlook depends on further operating efficiencies while NeoGenomics continues investing in sales, research, technology, and its testing pipeline. Compensation, supply costs, and tariffs could complicate that effort.
• Leadership transition adds execution risk: The CEO succession comes as the company is pursuing digital transformation, product expansion, and operational simplification, making continuity during the transition important.

Conclusion

NeoGenomics’ Q3 2026 results showed revenue growth driven more by higher-value testing and revenue per test than by overall volume. That mix shift, together with lower operating expenses, produced wider margins and sharply reduced GAAP losses, leading management to raise its full-year outlook. The main follow-up areas are whether NGS-led growth remains durable, margins continue expanding, and improved earnings translate into stronger operating cash flow.